Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Acrivon Therapeutics files to sell 15.29M shares of common stock for holders | 1 | Seeking Alpha | ||
Mi | Acrivon Therapeutics, Inc: Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress ... | 1 | GlobeNewswire (USA) | ||
10.04. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identifica | 76 | GlobeNewswire (Europe) | ACR-2316, which was internally discovered using biological SAR enabled by AP3 to overcome limitations of benchmark clinical WEE1 and PKMYT1 inhibitors, demonstrates potent anticancer activity in preclinical... ► Artikel lesen | |
09.04. | ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost | 3 | InvestorPlace | ||
09.04. | Acrivon Therapeutics Stock Is Soaring Tuesday: What's Going On? | 2 | Benzinga.com | ||
09.04. | HotStocks USA: +81 % bei Acrivon Therapeutics | 5 | stock3.com | ||
09.04. | Acrivon Therapeutics stock surges on $130M private placement financing | 3 | Seeking Alpha | ||
09.04. | Acrivon To Privately Place $130 Mln Of Shares; Stock Soars In Pre-market | 2 | RTTNews | ||
09.04. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
09.04. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Announces $130 Million Private Placement Financing | 2 | GlobeNewswire (USA) | ||
29.03. | Acrivon Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
28.03. | Acrivon Therapeutics: Q4 Earnings Insights | 1 | Benzinga.com | ||
28.03. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights | 93 | GlobeNewswire (Europe) | WATERTOWN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision... ► Artikel lesen | |
28.03. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
28.03. | Acrivon Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
05.03. | Acrivon Therapeutics, Inc: Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316 | 1 | GlobeNewswire (USA) | ||
04.03. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
27.02. | Acrivon Therapeutics, Inc: Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference | 1 | GlobeNewswire (USA) | ||
08.02. | Acrivon Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
06.02. | Acrivon Therapeutics, Inc: Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference | - | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 80,45 | -0,19 % | Biotech Report: Evotec klettern, Biontech leichter | (shareribs.com) Frankfurt / New York 12.04.2024 - Biotech-Aktien zeigen sich im deutschen Handel uneinheitlich. Evotec können zulegen, während es für 4SC und Qiagen abwärts geht. An der Wall Street... ► Artikel lesen | |
CUREVAC | 2,318 | +0,52 % | CureVac: Die Entscheidung fällt nächste Woche! | Arg strapaziert wurden zuletzt die Nerven von CureVac-Anteilseignern. So ergibt sich im Vergleich zur Vorwoche ein Minus von 2,95 Prozent. Insgesamt zwei der drei Handelstage beendete der Titel mit... ► Artikel lesen | |
AMGEN | 248,95 | +0,85 % | Amgen Aktie: Hoffnungsträger Tezspire trotz Studiendämpfer | Amgen lässt mit seinen Aktivitäten rund um das vielversprechende Medikament Tezspire aufhorchen. Trotz gemischter Ergebnisse in der Phase-2-Studie zur Behandlung von COPD, hat Wells Fargo das Rating... ► Artikel lesen | |
EPIGENOMICS | 1,595 | -2,45 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
NOVAVAX | 3,632 | -0,77 % | Schock-News für Novavax Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
BIOGEN | 179,50 | +0,31 % | What's in Store for Biogen (BIIB) This Earnings Season? | ||
MAINZ BIOMED | 0,870 | +0,81 % | MAINZ BIOMED N.V. - 6-K, Report of foreign issuer | ||
INTELLIA THERAPEUTICS | 19,895 | -0,72 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
DEFENCE THERAPEUTICS | 0,920 | -2,54 % | KI im Gesundheitswesen mit evotec, Defence Therapeutics, Bayer: Revolutionäre Fortschritte und medizinische Durchbrüche | Im Gesundheitswesen nimmt Künstliche Intelligenz (KI) immer mehr an Fahrt auf. KI-basierte Systeme können medizinische Datenbanken nutzen, um in der Forschung kostbare Zeit zu sparen, die es Unternehmen... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 4,203 | -0,71 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency | RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval... ► Artikel lesen | |
VIKING THERAPEUTICS | 61,36 | +0,92 % | Market Whales and Their Recent Bets on VKTX Options | ||
VAXART | 0,810 | +2,53 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the"Company"or"Vaxart") today announced that the Compensation Committee of the Board of Directors approved... ► Artikel lesen | |
EXELIXIS | 21,600 | +2,27 % | Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update | ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2023, provided an update on progress toward achieving... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 108,50 | -0,91 % | Sarepta Therapeutics Q4 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for Sarepta Therapeutics (SRPT):Earnings: $45.66 million in Q4 vs. -$109.24 million in the same period last year.
EPS: $0.47 in Q4... ► Artikel lesen | |
EXACT SCIENCES | 59,92 | +0,47 % | Exact Sciences names Aaron Bloomer as CFO |